Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB26FATZR
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,758
Award facts
- Contract value 100% obligated
- $18,757.69 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,757.69 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Dupixent 300 mg/2 ml pen injections. The award was issued on October 27, 2025, with an ultimate completion date of October 28, 2025, and utilizes firm fixed-price pricing with no set-aside designation. Performance will occur in Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the DOD pharmaceutical supply chain, with a wide product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's PPV-G GEN V contract, awarded in November 2025 with a ceiling value of $499,999,999 and completion date of December 31, 2036, positions it as a regional prime vendor contractor authorized to provide comprehensive pharmaceutical support to military healthcare facilities worldwide. This delivery order for Dupixent, a specialty pharmaceutical used in immunological treatments, exemplifies the company's role in fulfilling the specialized medication requirements of federal military medical operations.
Quick answers
Who was awarded contract SPE2DB26FATZR?
SPE2DB26FATZR was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FATZR worth?
The government has obligated $18,758 on SPE2DB26FATZR.
Is contract SPE2DB26FATZR an order under another contract?
Yes. SPE2DB26FATZR is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FATZR competed?
The extent of competition for SPE2DB26FATZR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award